Discharge β-blocker prescription after myocardial infarction (MI) is recommended for all eligible patients. It compares tight blood pressure control (aim: < 150/85 mmHg) versus less tight control (aim: < 180/105 mmHg) and, within the tight control group, an ACE inhibitor, captopril, versus a beta blocker, atenolol. But intermittent fasting is different. Their age-matched nondiabetic littermates db/m mice were treated with placebo and acted as nondiabetic controls. The use of ophthalmic beta-adrenergic receptor blocking agents (aka beta-blockers) is considered by manufacturers to be contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present). The purpose of this study is to evaluate the influence of genetic variation on beta-blocker-induced changes in insulin sensitivity, fat breakdown, and heart function in people with type 2 diabetes. The goal was to achieve and maintain a target blood pressure of ≤ 140/90 mm hg. These agents may expand the utility of beta-blockers to patient populations traditionally considered not to be optimal candidates for beta-blocker therapy-a fact which has important clinical implications, because more antihypertensive agents are needed to diversify the therapeutic options available for clinicians treating hypertension in patients with the cardiometabolic syndrome or type 2 diabetes. But they add that given the relative lack of clinical outcome data from trials of treating hypertension with beta blockers other than atenolol, concern about the generalizability of this conclusion, beyond atenolol to all beta blockers, remains. Thus, therapy with beta blockers appears to be associated with improved long-term survival in the high-risk subpopulation of patients with DM and CAD.